-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ReS-19T in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ReS-19T in Alzheimer's Disease Drug Details: ReS-19T is under development for the treatment of Alzheimer's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RE-104 in Treatment Resistant Depression
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RE-104 in Treatment Resistant Depression Drug Details: RE-104 is under development for the treatment...
-
Product Insights
![]()
Do-Re-Mi Upstream Project , Brazil
Do-Re-Mi upstream project is located in Sergipe, Brazil. The upstream project is owned by Centro Oeste Oleo e Gas Ltda (50%); Ubuntu Engineering & Services Ltd (50%). It will be operated by Ubuntu Engineering & Services Ltd. The project is currently in the planned stage and is expected to start operations in 2023. Do-Re-Mi Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well...
-
Product Insights
![]()
Buffalo (Re-Development) Upstream Project , Timor-Leste
Buffalo (Re-Development) upstream project is located in Timor Sea, Timor-Leste. The upstream project is owned by Carnarvon Petroleum Timor Unipessoal Lda. It will be operated by Carnarvon Petroleum Timor Unipessoal Lda. The project is currently in the announced stage and is expected to start operations in 2024. Buffalo (Re-Development) Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RE-104 in Post Partum Depression (Maternal Depression / Postnatal Depression)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RE-104 in Post Partum Depression (Maternal Depression / Postnatal Depression) Drug Details: RE-104 is...
-
![]()
Greystar RE – Mid85 Industrial Complex – South Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Greystar RE – Mid85 Industrial Complex – South Carolina report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:Dive deep...
-
![]()
Fiera RE/ HD Immobilier/ Omania Tech – CITIZIA Rental Tower – Quebec
Equip yourself with the essential tools needed to make informed and profitable decisions with our Fiera RE/ HD Immobilier/ Omania Tech – CITIZIA Rental Tower – Quebec report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
![]()
SCOA RE/ Velocis – Batavia Logistics Center – Illinois
Equip yourself with the essential tools needed to make informed and profitable decisions with our SCOA RE/ Velocis – Batavia Logistics Center – Illinois report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:Dive deep...
-
![]()
BPI RE Poland/ Revive Poland – Cavallia Mixed-Use Complex – Silesian Voivodeship
Equip yourself with the essential tools needed to make informed and profitable decisions with our BPI RE Poland/ Revive Poland – Cavallia Mixed-Use Complex – Silesian Voivodeship report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
![]()
United Kingdom (UK) Travel Insurance Market Dynamics, Trends and Opportunities
United Kingdom (UK) Travel Insurance Market Report Overview The UK travel insurance market witnessed a substantial increase in GWP reaching GBP 630.4 million in 2022. While the increase in GWP was substantial, it occurred in the context of a decrease in the number of policyholders. This suggests that growth in GWP is not due to increased demand but rather a result of higher premiums being charged. The market is expected to achieve a CAGR of more than 2% during 2022-2027. UK...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pyrimethamine in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pyrimethamine in Chronic Lymphocytic Leukemia (CLL) Drug Details: Pyrimethamine (GLG-801) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tebotelimab in Malignant Mesothelioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tebotelimab in Malignant Mesothelioma Drug Details: Tebotelimab (MGD-013) is under development for the treatment of...
-
![]()
CTR Partners/ PGIM RE – Garden State Logistics Center – New Jersey
Equip yourself with the essential tools needed to make informed and profitable decisions with our CTR Partners/ PGIM RE – Garden State Logistics Center – New Jersey report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Sector Analysis
![]()
Heart Failure Epidemiology Analysis and Forecast to 2032
Heart Failure Epidemiology Analysis Report Overview In the 7MM, there were 3,094,817 diagnosed incident cases of heart failure in 2022. The market is expected to grow at an AGR of more than 1% during 2022-2032. The Heart Failure market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for heart failure in the seven major markets namely the US, France, Germany, Italy, Spain, UK, and Japan. The report also includes a 10-year epidemiology...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Primary Sjogren’s Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Primary Sjogren's Syndrome Drug Details: Frexalimab (INX-021) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Relapsing Remitting Multiple Sclerosis (RRMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details: Frexalimab (INX-021) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details: Frexalimab (INX-021) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Relapsing Multiple Sclerosis (RMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Relapsing Multiple Sclerosis (RMS) Drug Details: Frexalimab (INX-021) is under development for the...
-
Thematic Analysis
![]()
Insurtech – Thematic Intelligence
Insurtech Thematic Report Overview Insurtechs can create innovative solutions for content generation using generative AI, risk modeling, and customer engagement. For instance, they can use generative AI to generate personalized insurance policies based on customer data, enhancing customer experiences and increasing policy uptake. Additionally, generative AI can be utilized to create interactive chatbots or virtual assistants that provide real-time support and streamline claims processing. Thus, by leveraging generative AI's ability to generate new content, insurtechs can also improve marketing efforts,...
-
Government & Regulation
![]()
Sudan Insurance Industry – Governance, Risk and Compliance
GlobalData’s ‘Sudan Insurance Industry – Governance, Risk and Compliance’ report is the result of extensive research into the insurance regulatory framework in Sudan. It provides detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation and transit insurance. The report specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries. The report brings together GlobalData’s research, modeling and analysis expertise, giving insurers access to information on prevailing...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.